Related Experiment Video

Updated: May 29, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

The clinical impact of galectin-8 in drug resistant breast cancer

Yi-Chung Chien1,2,3, Jia-Yan Wu1,2,3, Chi-Chun Pang2

  • 1Institute of Translational Medicine and New Drug Development, China Medical University, Taichung 406040, Taiwan.

Journal of Cancer
|February 3, 2025
PubMed

Insights

Researchers identified galectin-8 as a key regulator in breast cancer progression and multidrug resistance. Lowering galectin-8 expression restored drug sensitivity and reduced tumor growth, highlighting its therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer is a leading cause of cancer mortality in women worldwide.
  • Multidrug resistance (MDR) presents a significant challenge in effective breast cancer treatment.
  • Mechanisms of MDR include drug efflux, DNA repair, senescence escape, epigenetics, tumor heterogeneity, tumor microenvironment (TME) alterations, and epithelial-to-mesenchymal transition (EMT).

Purpose of the Study:

  • To identify novel genes involved in breast cancer progression and drug resistance.
  • To investigate the role of the identified gene, galectin-8, in modulating multidrug resistance in breast cancer.
  • To evaluate galectin-8 as a potential prognostic and therapeutic target for breast cancer.

Main Methods:

  • Analysis of The Cancer Genome Atlas (TCGA) data to identify candidate genes.
  • Gene Set Enrichment Analysis (GSEA) to assess galectin-8's role in drug resistance pathways.
  • Mass assay comparing drug-resistant and control triple-negative breast cancer (TNBC) cell lines.
  • Experimental manipulation of galectin-8 expression in TNBC cell lines.

Main Results:

  • Galectin-8 was identified as a novel gene critical for breast cancer progression.
  • GSEA indicated galectin-8's involvement in modulating breast cancer drug resistance.
  • Drug-resistant TNBC cell lines exhibited significantly higher galectin-8 expression compared to controls.
  • Reducing galectin-8 expression restored sensitivity to anticancer drugs and suppressed tumor cell proliferation and migration.

Conclusions:

  • Galectin-8 plays a significant role in breast cancer progression and the development of multidrug resistance.
  • Elevated galectin-8 expression is a marker of drug resistance in triple-negative breast cancer.
  • Targeting galectin-8 presents a promising therapeutic strategy for overcoming breast cancer drug resistance.
Keywords:
breast cancerdrug resistantgalectin-8prognosis

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.1K
Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

4.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K